New treatment strategies for bacterial meningitis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated by this lysis, adjunctive therapy to antimicrobial therapy has been investigated in experimental and clinical trials. This article reviews our present understanding of bacterial meningitis, the efficacy of dexamethasone in treatment, and the potential use of leukocyte monoclonal antibodies, pentoxifylline, nonsteroidal antiinflammatory agents, and anticytokine antibodies.

Original languageEnglish (US)
Pages (from-to)373-386
Number of pages14
JournalClinical Neuropharmacology
Volume16
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Bacterial Meningitides
Pentoxifylline
Subarachnoid Space
Non-Steroidal Anti-Inflammatory Agents
Dexamethasone
Leukocytes
Therapeutics
Monoclonal Antibodies
Clinical Trials
Anti-Bacterial Agents
Bacteria
Antibodies

Keywords

  • Anticytokine antibodies
  • Bacterial meningitis
  • Dexamethasone
  • Leukocyte monoclonal antibodies
  • Nonsteroidal antiinflammatory agents
  • Pentoxifylline

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

New treatment strategies for bacterial meningitis. / Roos, Karen.

In: Clinical Neuropharmacology, Vol. 16, No. 5, 1993, p. 373-386.

Research output: Contribution to journalArticle

@article{01ba52d3f2c5481c9ba865b6d4fea65d,
title = "New treatment strategies for bacterial meningitis",
abstract = "Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated by this lysis, adjunctive therapy to antimicrobial therapy has been investigated in experimental and clinical trials. This article reviews our present understanding of bacterial meningitis, the efficacy of dexamethasone in treatment, and the potential use of leukocyte monoclonal antibodies, pentoxifylline, nonsteroidal antiinflammatory agents, and anticytokine antibodies.",
keywords = "Anticytokine antibodies, Bacterial meningitis, Dexamethasone, Leukocyte monoclonal antibodies, Nonsteroidal antiinflammatory agents, Pentoxifylline",
author = "Karen Roos",
year = "1993",
language = "English (US)",
volume = "16",
pages = "373--386",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - New treatment strategies for bacterial meningitis

AU - Roos, Karen

PY - 1993

Y1 - 1993

N2 - Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated by this lysis, adjunctive therapy to antimicrobial therapy has been investigated in experimental and clinical trials. This article reviews our present understanding of bacterial meningitis, the efficacy of dexamethasone in treatment, and the potential use of leukocyte monoclonal antibodies, pentoxifylline, nonsteroidal antiinflammatory agents, and anticytokine antibodies.

AB - Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated by this lysis, adjunctive therapy to antimicrobial therapy has been investigated in experimental and clinical trials. This article reviews our present understanding of bacterial meningitis, the efficacy of dexamethasone in treatment, and the potential use of leukocyte monoclonal antibodies, pentoxifylline, nonsteroidal antiinflammatory agents, and anticytokine antibodies.

KW - Anticytokine antibodies

KW - Bacterial meningitis

KW - Dexamethasone

KW - Leukocyte monoclonal antibodies

KW - Nonsteroidal antiinflammatory agents

KW - Pentoxifylline

UR - http://www.scopus.com/inward/record.url?scp=0027383710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027383710&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 373

EP - 386

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -